Cargando…
Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.
Antibodies specific for human p53 were analysed in sera of lung cancer patients. We detected p53 antibodies in the sera of 24% (10/42) of patients with lung carcinoma. The distribution was as follows: 4/9 small-cell lung carcinomas (SCLCs), 2/18 squamous cell lung carcinomas (SCCs), 2/10 adenocarcin...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968913/ https://www.ncbi.nlm.nih.gov/pubmed/7514026 |
_version_ | 1782134844215525376 |
---|---|
author | Schlichtholz, B. Trédaniel, J. Lubin, R. Zalcman, G. Hirsch, A. Soussi, T. |
author_facet | Schlichtholz, B. Trédaniel, J. Lubin, R. Zalcman, G. Hirsch, A. Soussi, T. |
author_sort | Schlichtholz, B. |
collection | PubMed |
description | Antibodies specific for human p53 were analysed in sera of lung cancer patients. We detected p53 antibodies in the sera of 24% (10/42) of patients with lung carcinoma. The distribution was as follows: 4/9 small-cell lung carcinomas (SCLCs), 2/18 squamous cell lung carcinomas (SCCs), 2/10 adenocarcinomas (ADCs) and 2/5 large-cell lung carcinomas (LCCs). p53 antibodies were always present at the time of diagnosis and did not appear during progression of the disease. Using an original peptide-mapping procedure, we precisely localised the p53 epitopes recognised by p53 antibodies. Immunodominant epitopes reacting with antibodies were localised in the amino and carboxy termini of the protein, similar to those found in breast carcinoma patients or in animals immunised with p53. In light of these data, we suggest that p53 antibodies occur via a self-immunisation process that is the consequence of p53 accumulation in tumour cells. p53 antibodies were also detected in two patients without detected malignant disease. One of these patients died 6 months later of lung carcinoma, suggesting that p53 antibodies may be a precocious marker of p53 alteration. IMAGES: |
format | Text |
id | pubmed-1968913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1994 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19689132009-09-10 Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Schlichtholz, B. Trédaniel, J. Lubin, R. Zalcman, G. Hirsch, A. Soussi, T. Br J Cancer Research Article Antibodies specific for human p53 were analysed in sera of lung cancer patients. We detected p53 antibodies in the sera of 24% (10/42) of patients with lung carcinoma. The distribution was as follows: 4/9 small-cell lung carcinomas (SCLCs), 2/18 squamous cell lung carcinomas (SCCs), 2/10 adenocarcinomas (ADCs) and 2/5 large-cell lung carcinomas (LCCs). p53 antibodies were always present at the time of diagnosis and did not appear during progression of the disease. Using an original peptide-mapping procedure, we precisely localised the p53 epitopes recognised by p53 antibodies. Immunodominant epitopes reacting with antibodies were localised in the amino and carboxy termini of the protein, similar to those found in breast carcinoma patients or in animals immunised with p53. In light of these data, we suggest that p53 antibodies occur via a self-immunisation process that is the consequence of p53 accumulation in tumour cells. p53 antibodies were also detected in two patients without detected malignant disease. One of these patients died 6 months later of lung carcinoma, suggesting that p53 antibodies may be a precocious marker of p53 alteration. IMAGES: Nature Publishing Group 1994-05 /pmc/articles/PMC1968913/ /pubmed/7514026 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Schlichtholz, B. Trédaniel, J. Lubin, R. Zalcman, G. Hirsch, A. Soussi, T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
title | Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
title_full | Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
title_fullStr | Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
title_full_unstemmed | Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
title_short | Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
title_sort | analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968913/ https://www.ncbi.nlm.nih.gov/pubmed/7514026 |
work_keys_str_mv | AT schlichtholzb analysesofp53antibodiesinseraofpatientswithlungcarcinomadefineimmunodominantregionsinthep53protein AT tredanielj analysesofp53antibodiesinseraofpatientswithlungcarcinomadefineimmunodominantregionsinthep53protein AT lubinr analysesofp53antibodiesinseraofpatientswithlungcarcinomadefineimmunodominantregionsinthep53protein AT zalcmang analysesofp53antibodiesinseraofpatientswithlungcarcinomadefineimmunodominantregionsinthep53protein AT hirscha analysesofp53antibodiesinseraofpatientswithlungcarcinomadefineimmunodominantregionsinthep53protein AT soussit analysesofp53antibodiesinseraofpatientswithlungcarcinomadefineimmunodominantregionsinthep53protein |